1 rich Libsyn https://www.libsyn.com 90 600 Episode 348 (Part 1) hosts David Moatazedi (President &amp;amp; CEO of Evolus from California, USA). In this podcast we cover Evolus’ global vision and strategy - based on shifting from a traditional pharma model toward “performance beauty”. Our conversation with David discusses market differences by country, rapid trend cycles and the need for continuing clinical evidence. We address the drop in global HA fillers, macroeconomics, pipeline strategy and future modalities. &amp;nbsp; 00:00 Aesthetics Industry Shift Ahead 00:52 Show Introduction and Two-Part Format 02:14 Meet David and the Evolus Story 03:35 Evolus’ North Star for Growth 05:08 Beauty Lens vs Medical Risk 08:34 How the Industry Is Maturing Worldwide 10:36 Hype Cycles and Long-Term Staying Power 13:56 The “Natural Look” and Trend Drivers 17:37 Why Evolus Went Public 19:34 Macro Risks and Pipeline Bets 22:21 The Future of HA Fillers 22:48 Why HA Fillers Have Slowed Down 24:12 Rebranding the Filler Category 26:22 Staying Customer-Centric 28:53 The Next Waves of Innovation 31:49 Robots and AI Injectors 33:05 Helping Clinics Grow 37:31 Launching in Australia 38:45 What Aesthetics Could Look Like in 2035 41:33 Pipeline Updates and New HA Technology 43:07 Wrap-Up and Where to Watch 30 DAY FREE TRIAL OF IA COMMUNITY (FOR HEALTHCARE PROFESSIONALS) 30 DAY FREE TRIAL OF IA COMMUNITY (FOR BUSINESS OWNERS/NON-CLINICAL PROFESSIONALS) ALL OTHER IA LINKS &amp;amp; CONTACT INFORMATION Inside Aesthetics Podcast https://www.solo.to/insideaesthetics <iframe title="Libsyn Player" style="border: none" src="//html5-player.libsyn.com/embed/episode/id/36063805/height/90/theme/custom/thumbnail/yes/direction/forward/render-playlist/no/custom-color/88AA3C/" height="90" width="600" scrolling="no" allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen></iframe> https://assets.libsyn.com/secure/content/186805665